Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Abstract After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retrial as a treatment strategy is commonplace in modern clinical practi...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Nicholas Mai, Carlos H. dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Z. Drago, Shanu Modi, Jacqueline F. Bromberg, Chau T. Dang, Dazhi Liu, Larry Norton, Mark Robson, Sarat Chandarlapaty, Komal Jhaveri
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Nature Portfolio 2024-10-01
Serie:	npj Breast Cancer
Länkar:	https://doi.org/10.1038/s41523-024-00699-3
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!